uniQure N.V.
QURE
NASDAQ
IPO2014
about QURE
uniQure N.V. is a biotechnology company specializing in gene therapy treatments, with its primary focus on developing EvoxTM, an innovative treatment for hemophilia A that addresses the root cause of the disease by delivering a healthy copy of the factor IX gene.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $39.36 | $51.21 | $37.12 | $749.48M | 67.21M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.69 | n/a | 496.42 | -833.62% | -716.82% | 0% |